Johnson And Johnson

J&J ordered to pay record $966 million in talc baby powder cancer case

The verdict comes amid over 70,000 pending claims accusing J&J of talc-related cancers, with many cases consolidated before a federal judge in New Jersey for pre-trial proceedings

Dr Reddy's signs pact with J&J to acquire vertigo treatment brand

Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..

J&J tops Q1 forecasts as cancer drugs drive growth; sales outlook raised

On an adjusted basis, the company earned $2.77 per share in the quarter, 2.2 per cent higher than the previous year and above analysts' estimates of $2.59 per share

Bankruptcy judge rejects J&J's talc baby powder related settlement plan

A US bankruptcy court judge has denied Johnson & Johnson's settlement plan related to baby powder containing talc, providing another setback in the company's efforts to resolve the matter. This is the third bankruptcy case for a J&J company as it relates to the baby powder issue. Red River Talc LLC, a J&J subsidiary, was seeking confirmation of a proposed prepackaged Chapter 11 bankruptcy plan that would have been one of the biggest mass tort settlements in history, if approved. Red River and J&J proposed to pay USD 9 billion to settle ovarian cancer and other gynecological cancer litigation claims based on talc-related products. But Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston division said in a court filing that J&J used a faulty voter solicitation process when dealing with personal injury claimants. J&J said in a statement that it will not pursue an appeal, and instead will return to the civil law system to ..

Johnson & Johnson's plan for bankruptcy to end talc cancer claims rejected

US Bankruptcy Judge Christopher Lopez on Monday dismissed the bankruptcy of a small J&J unit called Red River Talc following a two-week trial in Houston

Johnson & Johnson increases US investment to over $55 bn over next 4 yrs

Johnson and Johnson, US healthcare's leading, most comprehensive innovation powerhouse, announced on Friday that it will invest more than USD 55 billion in manufacturing, research and development, and technology in the United States over the next four years.According to Johnson and Johnson's statement, this represents a 25 per cent increase in investment compared to the previous four years and builds upon the Company's already elevated US investment levels resulting from the passage of the 2017 Tax Cuts & Jobs Act."Today's announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world's toughest healthcare challenges," said Joaquin Duato, Chairman and Chief Executive Officer of Johnson and Johnson. "Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world."In addition to

J&J plans to invest more than $55 billion in US over the next 4 years

The drug and device maker said this represents an increase of 25% in investment compared to the past four years

J&J begins critical court hearing over $10 billion baby powder settlement

The judge will listen to supporters and opponents of J&J's bankruptcy proposal in a marathon court hearing that will last until the end of February

J&J Q3 earnings beat expectations, make progress on talc liabilities

Adjusted profit was $2.42 a share, surpassing Wall Street's average estimate of $2.19. Pharmaceutical revenue rose almost 5 per cent, exceeding expectations by more than $400 million

J&J raises baby powder settlement offer to more than $8.2 billion

J&J recently garnered support from more than 75 per cent of baby powder claimants for an out-of-court deal that includes claims that the talc-based version caused ovarian and other gynecological cance

Johnson & Johnson to pay additional $1.1 bn to resolve talc settlement

The increase would boost the size of the settlement to more than $9 billion paid over 25 years

US court jury directs J&J to pay $260 million to baby powder user

J&J now faces more than 61,000 suits blaming talc for different types of cancers. Many of the cases have been consolidated before a federal judge in New Jersey

WHO says wider warning about contaminated J&J cough syrup 'likely'

Nigeria's regulator recalled a batch of Benylin syrup last Wednesday, having found a high level of diethylene glycol in the product during routine testing

J&J Q1 results: Profit beats expectations on cancer drugs strength

Sales of its blockbuster psoriasis drug Stelara were flat at $2.45 billion in the first quarter, while sales of Darzalex jumped about 19% to $2.69 billion

J&J can contest evidence linking its talc to ovarian cancer, says US judge

Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016

Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug

Biocon said that the U.S. FDA has accepted the Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway

J&J to pay $700 mn to settle talc investigation by more than 40 US states

Shares of J&J fell slightly as trading began Monday morning in New York, but closed with a 0.25 per cent gain at $161.53. The stock fell 11 per cent last year

J&J, Lupin cut prices for tuberculosis drug in lower-income countries

(Reuters) - Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tuberculosis group said on Wednesday.

J&J can't use bankruptcy to settle 100,000 baby powder cancer claims: Judge

J&J shares dropped as much as 3.4% in post-market trading following the ruling. The company vowed to appeal Judge Kaplan's ruling

J&J sues US govt to block Medicare drug price negotiation plans: Report

Pharmaceutical industry says the drug price negotiation program that is part of President Joe Biden's IRA will curtail profits and compel them to pull back on developing groundbreaking new treatment